tokens: Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non-small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 %. Leukopenia was dose limiting : as many as 62 .